Can shoulder cartilage damage be treated without surgery?

For focal shoulder cartilage damage, a surgical pathway is no longer the only option. ChondroFiller® is a CE-marked injectable collagen scaffold approved for glenohumeral joint defects alongside the knee, hip, ankle, elbow, and wrist — and at London Cartilage Clinic on Harley Street it is delivered as an ultrasound-guided outpatient injection: no general anaesthetic, no theatre booking, no surgical incision.

The gel is placed percutaneously under real-time ultrasound imaging, guided directly into the defect site. Some manufacturer literature and surgical research describe an earlier arthroscopic delivery route; the current clinical pathway at London Cartilage Clinic is injection-only, which keeps the entire procedure at outpatient level and avoids the joint-drying and debridement steps that arthroscopic implantation requires.

Not every shoulder presentation is suitable for this route. The treatment targets focal Grade III or IV chondral defects — discrete areas of cartilage loss with healthy surrounding borders. Diffuse osteoarthritis and bone-on-bone joint space narrowing fall outside the indication. This matters especially in the shoulder, where cartilage lesions are notoriously difficult to identify: many patients arrive with a longstanding diagnosis of impingement syndrome or instability rather than a confirmed structural defect. MRI confirmation of a focal glenohumeral lesion is an essential prerequisite, and most patients will need that imaging before a clinical assessment of suitability can be completed.

Why shoulder cartilage damage is so often missed

Months of physiotherapy for what appeared to be shoulder impingement — and still the pain persists. This is a familiar presentation, and the reason is not diagnostic error so much as anatomical reality. The glenohumeral cartilage surface is deeply recessed within the joint, inaccessible to direct palpation, and the symptoms it produces — aching at rest, pain on certain movements, a vague sense of grinding — overlap almost entirely with rotator-cuff irritation, labral problems, and subacromial impingement. Standard clinical examination, however thorough, cannot reliably tell these conditions apart.

This matters because a focal chondral defect and a tendon problem require fundamentally different treatments. Without imaging, the cartilage surface simply cannot be assessed, and an unrecognised defect will not respond to impingement-directed therapy.

MRI of the glenohumeral joint — sometimes supplemented by an arthrogram in selected cases — is the only reliable way to confirm cartilage damage, establish its grade, and determine whether the surrounding borders are intact enough to contain a scaffold. For patients whose shoulder pain has plateaued despite appropriate conservative management, a specific review of the articular cartilage on imaging is a reasonable and often overdue step.

The injection pathway for ChondroFiller® only opens once imaging has confirmed a focal defect. Without that confirmation, neither the indication nor the containment conditions required for the scaffold can be verified.

Which shoulder patients are suitable for the ChondroFiller injection

The clearest candidates are patients with a confirmed focal chondral defect — typically Grade III or IV — where the surrounding cartilage remains structurally intact. That intact border is what allows the collagen gel to be contained and held in position while it sets; without it, the scaffold has no wall to gel against. Post-traumatic presentations fit this profile well: a direct impact, a dislocation event, or a sports injury that has left a discrete area of cartilage loss on MRI, with the rest of the joint surface largely unaffected. Lesions found incidentally during imaging for another shoulder complaint — and confirmed on review to be focal and contained — are also a recognised referral route.

Several presentations fall outside the indication. Diffuse osteoarthritis involving the whole glenohumeral surface, bone-on-bone joint-space loss, and bipolar lesions where both the humeral head and glenoid are damaged are not suitable for this injectable scaffold approach. Active joint infection and systemic inflammatory arthritis in acute flare are also contraindications, as is known sensitivity to collagen.

Age and activity level are not absolute bars. The procedure has been used in active patients and in older adults where imaging confirms the damage is localised. Whether a specific presentation meets the criteria is a clinical determination — patients who are uncertain about their imaging findings or suitability should arrange a formal assessment rather than self-selecting in or out on the basis of symptoms alone.

How the ChondroFiller injection works once it is in the joint

Inside the joint, ChondroFiller® works through a process called acellular matrix-induced chondrogenesis — a term that describes precisely what happens: a scaffold with no cells of its own prompts the body to send its own repair cells into the defect.

The practical sequence begins with the syringe itself. ChondroFiller® is supplied in a ready-to-use two-chamber format containing a native Type I collagen solution and a neutralisation agent in separate compartments. The two components mix only at the needle tip during delivery, so there is nothing to prepare in advance and no window in which the product can degrade before use.

Once placed into the defect under ultrasound guidance, the mixed collagen gels into a dimensionally stable hydrogel scaffold within approximately 3–5 minutes. It conforms to the shape of the lesion and holds its position — crucially, without any bone drilling, biopsy, fibrin glue, or mechanical fixation. The scaffold is designed to function in a fluid joint environment, which is precisely what makes the outpatient injection route viable.

The scaffold itself contains no donor cells and no patient-harvested tissue. It acts instead as a chemotactic matrix — a structured signal that recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone into the defect space. Those cells gradually differentiate and deposit new cartilage-like tissue within the scaffold over the following months.

This is not a rapid process. Published experience indicates a repair window of 6–24 months, with progressive tissue maturation rather than a single point of recovery. Structured rehabilitation supports this gradual process; without it, outcomes are likely to be suboptimal.

What outcomes to expect — and what the evidence actually covers

The published ChondroFiller® outcome figures come from the knee and hip, not from glenohumeral-specific trials — a point worth stating at the front rather than in a footnote.

In knee studies, mean IKDC scores improved by approximately 30 points, with the Jerosch et al. post-market clinical follow-up study recording a mean gain of 32.4 points sustained and slightly increased at three-year follow-up, reaching a functional score of 80 — well above the established minimum clinically important difference of 16.7. MOCART MRI scoring, which measures defect filling and tissue integration, ranged from 81.6 to 84.3 across European knee cohorts, with scores improving from 65.3 at four weeks to 81.6 at one year, demonstrating progressive tissue maturation rather than immediate repair. Hip studies show a mean Harris Hip Score gain of approximately 33 points. Across knee, hip, and small-joint cohorts combined, published series report 70–85% of treated patients achieving significant symptom relief, out of more than 19,000 cases performed globally.

For a shoulder patient, the honest read of these figures is that they represent the best available inference, not a glenohumeral-specific guarantee. The scaffold mechanism and patient-selection criteria are consistent across joints, and the shoulder is a listed CE-approved indication — but dedicated glenohumeral trials do not yet exist. A wider confidence interval than the knee figures suggest is the appropriate starting assumption. What this means practically is that any shoulder assessment should include an explicit conversation about where the supporting data comes from and what it can and cannot confirm for this particular joint. The absence of glenohumeral-specific trial data is not a reason to rule the procedure out, but it is a reason to ask the question.

Outcome quality is also sensitive to delivery. Accurate ultrasound-guided placement and a structured post-injection rehabilitation programme are prerequisites for achieving results comparable to those in published series — not optional extras that can be deferred once the injection is done.

Getting a ChondroFiller injection for the shoulder in the UK

ChondroFiller injection is available in the UK as a self-funded private treatment — there is no NHS commissioning pathway and no FDA clearance, which restricts geographic access primarily to Europe.

The guide cost starts at approximately £3,000 at London Cartilage Clinic, covering consultation, ultrasound imaging, the product, the injection, intravenous antibiotic cover, and a six-week follow-up. An initial consultation includes imaging review and clinical evaluation to confirm whether the defect meets selection criteria; the final cost is confirmed at that stage rather than fixed in advance.

Precise scaffold placement and structured post-injection physiotherapy are prerequisites for achieving results comparable to published series — a point that makes the choice of treating clinician material rather than incidental. Questions worth raising at any assessment include the practitioner's specific experience with ultrasound-guided delivery to the glenohumeral joint, the clinic's rehabilitation protocol, and how repair tissue maturation will be monitored across the 6–24 month window.

London Cartilage Clinic on Harley Street was the first UK centre to offer ChondroFiller® as an ultrasound-guided outpatient injection and remains the UK's certified delivery centre for the product, led by Professor Paul Y. F. Lee.

To book an assessment, visit londoncartilage.com.